Icure Pharmaceutical Inc
175250
Company Profile
Business description
Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.
Contact
7, Saimdang-ro 1-gil
Seocho-gu
Seoul
KORT: +82 269596909
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
293
Stocks News & Analysis
stocks
Is this ASX share a long-term buy?
Current operating conditions are challenging but over the long-term prospects are better.
stocks
Why Guzman and Reece's share reversals have a lot in common
Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,477.30 | 20.70 | -0.24% |
CAC 40 | 8,137.26 | 86.19 | 1.07% |
DAX 40 | 22,732.24 | 321.97 | 1.44% |
Dow JONES (US) | 43,758.96 | 137.80 | 0.32% |
FTSE 100 | 8,722.03 | 53.36 | 0.62% |
HKSE | 23,787.93 | 753.91 | 3.27% |
NASDAQ | 19,196.80 | 170.41 | 0.90% |
Nikkei 225 | 38,142.37 | 95.42 | -0.25% |
NZX 50 Index | 12,452.46 | 145.19 | 1.18% |
S&P 500 | 5,991.45 | 36.20 | 0.61% |
S&P/ASX 200 | 8,240.70 | 11.20 | -0.14% |
SSE Composite Index | 3,380.21 | 34.17 | 1.02% |